These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 8383104

  • 1. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R, Andrews JM, Brenwald N.
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [Abstract] [Full Text] [Related]

  • 2. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    Cooper MA, Andrews JM, Ashby JP, Matthews RS, Wise R.
    J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
    [Abstract] [Full Text] [Related]

  • 3. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A.
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [Abstract] [Full Text] [Related]

  • 4. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA, García Sánchez JE, García García MI, Fresnadillo MJ, Trujillano I, García Sánchez E.
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [Abstract] [Full Text] [Related]

  • 5. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R, Brenwald NP, Andrews JM, Boswell F.
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [Abstract] [Full Text] [Related]

  • 7. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R, Andrews JM, Brenwald N.
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [Abstract] [Full Text] [Related]

  • 8. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN, Ballow CH, Schentag JJ, Johnson DM, Deinhart JA.
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A, Petersen U, Endermann R.
    Chemotherapy; 1996 May; 42(6):410-25. PubMed ID: 8957575
    [Abstract] [Full Text] [Related]

  • 10. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN, Barrett MS, Erwin ME, Briggs BM, Johnson DM.
    Diagn Microbiol Infect Dis; 1991 May; 14(4):319-30. PubMed ID: 1909615
    [Abstract] [Full Text] [Related]

  • 11. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS, Mazens-Sullivan MF, Bartlett RC.
    Chemotherapy; 1992 May; 38(5):308-18. PubMed ID: 1337507
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH, Jones RN, Johnson DM, Deinhart JA, Schentag JJ.
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [Abstract] [Full Text] [Related]

  • 13. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
    Child J, Andrews J, Boswell F, Brenwald N, Wise R.
    J Antimicrob Chemother; 1995 Jun; 35(6):869-76. PubMed ID: 7559198
    [Abstract] [Full Text] [Related]

  • 14. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C, Voss A, Milatovic D, Braveny I.
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [Abstract] [Full Text] [Related]

  • 15. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 16. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
    Aldridge KE.
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
    García-Rodríguez JA, García-Sánchez JE, Trujillano-Martín I, García-Sánchez E, García-García MI, Fresnadillo-Martínez MJ.
    J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
    [Abstract] [Full Text] [Related]

  • 18. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics.
    Chin NX, Neu HC.
    J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856
    [Abstract] [Full Text] [Related]

  • 19. The in-vitro activity of two new quinolones: rufloxacin and MF 961.
    Wise R, Andrews JM, Matthews R, Wolstenholme M.
    J Antimicrob Chemother; 1992 Jun; 29(6):649-60. PubMed ID: 1324239
    [Abstract] [Full Text] [Related]

  • 20. Activity of BAY y 3118, a novel 4-quinolone, against Brucella melitensis.
    García-Rodríguez JA, García-Sánchez JE, Trujillano-Martín I, García-Sánchez E, García-García MI, Fresnadillo MJ.
    J Chemother; 1994 Apr; 6(2):102-6. PubMed ID: 8077983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.